Rheumatology Department, Dumfries and Galloway Royal Infirmary, Cargenbridge, Dumfries, UK.
School of Health and Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow,, G4 0BA, UK.
Clin Rheumatol. 2021 Sep;40(9):3445-3454. doi: 10.1007/s10067-020-05355-2. Epub 2020 Sep 2.
To develop recommendations for the management of rheumatic and musculoskeletal diseases (RMDs) during the COVID-19 pandemic.
A task force comprising of 25 rheumatologists from the 5 regions of the continent was formed and operated through a hub-and-spoke model with a central working committee (CWC) and 4 subgroups. The subgroups championed separate scopes of the clinical questions and formulated preliminary statements of recommendations which were processed centrally in the CWC. The CWC and each subgroup met by several virtual meetings, and two rounds of voting were conducted on the drafted statements of recommendations. Votes were online-delivered and recommendations were pruned down according to predefined criteria. Each statement was rated between 1 and 9 with 1-3, 4-6 and 7-9 representing disagreement, uncertainty and agreement, respectively. The levels of agreement on the statements were stratified as low, moderate or high according to the spread of votes. A statement was retired if it had a mean vote below 7 or a 'low' level of agreement.
A total of 126 initial statements of recommendations were drafted, and these were reduced to 22 after the two rounds of voting.
The preliminary statements of recommendations will serve to guide the clinical practice of rheumatology across Africa amidst the changing practices and uncertainties in the current era of COVID-19. It is recognized that further updates to the recommendations will be needed as more evidence emerges. Key Points • AFLAR has developed preliminary recommendations for the management of RMDs in the face of the COVID-19 pandemic. • COVID-19 is an unprecedented experience which has brought new concerns regarding the use of some disease-modifying anti-rheumatic drugs (DMARDs), and these recommendations seek to provide guidelines to the African rheumatologists. • Hydroxychloroquine shortage has become rampart across Africa as the drug is being used as prophylaxis against COVID-19 and this may necessitate a review of treatment plan for some patients with RMDs. • Breastfeeding should continue for as long as possible if a woman is positive for SARS-CoV-2 as there is currently no evidence that the infection can be transmitted through breast milk.
制定在 COVID-19 大流行期间管理风湿和肌肉骨骼疾病(RMD)的建议。
成立了一个由来自大陆 5 个地区的 25 名风湿病专家组成的工作组,通过中央工作组(CWC)和 4 个分组的中心辐射型模式运作。分组分别负责不同临床问题的范围,并制定初步建议声明,这些声明在 CWC 进行集中处理。CWC 和每个分组都通过多次虚拟会议进行了会议,并对建议草案进行了两轮投票。投票是在线进行的,建议根据预定义的标准进行修剪。每个声明的评分范围为 1 到 9 分,1-3 分、4-6 分和 7-9 分分别表示不同意、不确定和同意。根据投票的分布情况,将声明的一致性分为低、中和高三个层次。如果平均投票低于 7 分或一致性为“低”,则该声明将被退休。
共起草了 126 项初步建议声明,经过两轮投票后,这些声明减少到 22 项。
在当前 COVID-19 时代,随着实践和不确定性的不断变化,这些初步建议声明将有助于指导非洲的风湿病临床实践。认识到随着更多证据的出现,需要对建议进行进一步更新。关键点:
AFLAR 在面对 COVID-19 大流行时制定了 RMD 管理的初步建议。
COVID-19 是一次前所未有的经历,它引起了人们对某些疾病修饰抗风湿药物(DMARDs)使用的新关注,这些建议旨在为非洲风湿病学家提供指导。
羟氯喹在非洲各地短缺,因为该药物被用作 COVID-19 的预防药物,这可能需要重新审查一些 RMD 患者的治疗计划。
如果妇女对 SARS-CoV-2 呈阳性,应尽可能长时间地继续母乳喂养,因为目前没有证据表明感染可以通过母乳传播。